ストックスクリーナーアプリを入手
81.89
3.82%
3.01
アフターアワーズ：
81.89
Dianthus Therapeutics Inc (DNTH) 最新ニュース
DNTH stock clocks best day in over 3 months on strong nerve disorder study results - MSN
Dianthus drops as Sanofi halts late-stage trial for CIDP therapy on efficacy concerns - MSN
DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results - TradingView
Why Is Dianthus Therapeutics Stock Trading Higher On Friday? - Benzinga
Dianthus Therapeutics posts interim CAPTIVATE responder data; 75% response in first 40 CIDP patients - TradingView
Dianthus Therapeutics (DNTH) details interim Phase 3 CIDP results, Phase 2 gMG data and $1.2B runway - Stock Titan
Dianthus Therapeutics: Sanofi's CIPD Study Fail Poses Uncomfortable Questions - Seeking Alpha
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says - Benzinga
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says - Sahm
Guggenheim reiterates Dianthus stock rating citing potency edge By Investing.com - Investing.com Nigeria
Dianthus Therapeutics Down Over 9%, On Track for Largest Percent Decrease Since January 2025 -- Data Talk - Moomoo
Dianthus Therapeutics stock rating maintained at Buy by TD Cowen - Investing.com Canada
Dianthus Therapeutics stock falls on Sanofi CIDP trial halt By Investing.com - Investing.com South Africa
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch? - BioWorld News
Truist reiterates Dianthus Therapeutics stock rating after rival trial halt By Investing.com - Investing.com Canada
Sanofi (SNY) Halts Phase 3 Study, Impacting Dianthus Therapeutics - GuruFocus
Why is Dianthus Therapeutics stock plunging today? By Investing.com - Investing.com Canada
Stifel reiterates Dianthus Therapeutics stock Buy on rival setback By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Will Orphan Drug Status And Advancing Autoimmune Pipeline Change Dianthus Therapeutics' (DNTH) Narrative - Yahoo Finance
DNTH: Advancing potent neuromuscular and rheumatology assets with robust funding and rapid execution - TradingView
DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch - Stocktwits
Gross profit of Dianthus Therapeutics, Inc. – XETR:87E - TradingView
Net debt of Dianthus Therapeutics, Inc. – XETR:87E - TradingView
Enterprise value of Dianthus Therapeutics, Inc. – XETR:87E - TradingView
Net income before discontinued operations of Dianthus Therapeutics, Inc. – XETR:87E - TradingView
Return on equity % of Dianthus Therapeutics, Inc. – XETR:87E - TradingView
Dianthus Therapeutics, Inc. Balance Sheet – XETR:87E - TradingView
Dianthus Therapeutics, Inc. Statistics – XETR:87E - TradingView
BNP Paribas Financial Markets Boosts Stake in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Assessing Dianthus Therapeutics (DNTH) Valuation After FDA Eases Claseprubart Trial Screening Rules - Sahm
Dianthus Therapeutics (DNTH) Appears Attractive Amid Solid Product Pipeline - Insider Monkey
DNTH: Multiple pivotal trials advance with key data and strong cash runway supporting growth - TradingView
Dianthus Therapeutics Inc (DNTH): FDA Makes Trials Easier - Yahoo Finance
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Dianthus Therapeutics EVP Randhawa sells $2.4m in company stock By Investing.com - Investing.com South Africa
Dianthus Therapeutics EVP Randhawa sells $2.4m in company stock - Investing.com
Dianthus Therapeutics (DNTH) EVP sells 26,530 shares after option exercises - Stock Titan
DNTH (NASDAQ) director files Form 144 to sell 26,530 shares - Stock Titan
Top Avalyn Pharma (AVLN) Competitors 2026 - MarketBeat
Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win (NASDAQ:DNTH) - Seeking Alpha
Dianthus Therapeutics (DNTH) Surges 4.37% as Stock Nears Key Resistance LevelDemand Zone - The Legal Advocate
DNTH Stock Price, Quote & Chart | DIANTHUS THERAPEUTICS INC (NASDAQ:DNTH) - ChartMill
Biotech Dianthus to meet investors at Jefferies and Goldman events - Stock Titan
Dianthus Therapeutics to Participate in Two Investor Conferences - Yahoo Finance
Dianthus Therapeutics (DNTH) Declines Amid Sector Pressure, Support Levels in FocusRevenue Weighted - The Legal Advocate
Dianthus Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineDownward Estimate Revision - newsline.com
Dianthus Therapeutics Q1 2026 Earnings: Better-than-Expected Loss Despite No RevenuePost-Earnings Drift - The Legal Advocate
Dianthus (DNTH) director receives 6,090 options vesting by 2027 - Stock Titan
Dianthus Therapeutics (DNTH) awards director 6,090 stock options at $89.63 - Stock Titan
Director at Dianthus Therapeutics (DNTH) granted 6,090 stock options - Stock Titan
Dianthus (DNTH) director Jonathan Violin receives grant of 6,090 stock options - Stock Titan
2.60%
0.94%
大文字化:
|
ボリューム (24 時間):